Helsinn Healthcare S.A.: ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
Helsinn Healthcare S.A.: ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, "Helsinn") and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara; "ONO") announced today that ONO received the manufacturing and marketing approval of Adlumiz (generic name: anamorelin hydrochloride) Tablet 50mg ("Adlumiz"), a ghrelin re...
Source: finanznachrichten.de